Adiponectin Counteracts Cytokine- and Fatty Acid-induced Apoptosis in the Pancreatic Beta-cell Line INS-1
Overview
Authors
Affiliations
Aims/hypothesis: Pancreatic beta-cell apoptosis is a common feature of Type 1 and Type 2 diabetes and leptin exerts an anti-apoptotic function in these cells. The beta-cell line INS-1 was used to test the hypothesis that the adipocyte hormone adiponectin might mediate an anti-apoptotic effect comparable to leptin.
Methods: Apoptosis was induced by culturing cells with a cytokine combination (interleukin-1beta/interferon-gamma) or palmitic acid in absence or presence of leptin or the globular domain of adiponectin (gAcrp30), respectively.
Results: INS-1 cells had a prominent sensitivity towards cytokine- and fatty acid-induced apoptosis, resulting in about three- and six-fold increases in caspase 3 activation and DNA fragmentation, respectively. gAcrp30 strongly (50-60%) inhibited palmitic acid-induced apoptosis, with a weaker effect against cytokine-induced apoptosis (35%). The same result was observed for leptin with both adipokines being non-additive. Reduction of apoptosis by an inhibitor of IkappaB-kinase (IKK) indicated the involvement of the nuclear factor (NF)-kappaB pathway in both cytokine- and fatty acid-induced apoptosis, however, leptin and gAcrp30 were unable to block NF-kappaB activation. Cytokine- and fatty-acid-induced suppression of glucose/forskolin-stimulated insulin secretion was completely prevented through the action of gAcrp30, whereas leptin was only effective against lipotoxicity-mediated beta-cell dysfunction.
Conclusion/interpretation: Our data show that gAcrp30 partially rescues beta cells from cytokine- and fatty-acid-induced apoptosis and completely restores autoimmune- and lipotoxicity-induced dysfunction of insulin-producing cells. We suggest that gAcrp30 exerts its anti-apoptotic function without modulating NF-kappaB activation. This novel beta cell protective function of gAcrp30 might serve to counteract autoimmune- and lipotoxicity-induced beta-cell destruction.
Adiponectin: A Promising Target for the Treatment of Diabetes and Its Complications.
Begum M, Choubey M, Tirumalasetty M, Arbee S, Mohib M, Wahiduzzaman M Life (Basel). 2023; 13(11).
PMID: 38004353 PMC: 10672343. DOI: 10.3390/life13112213.
Hashim K, Chin K, Ahmad F Molecules. 2023; 28(6).
PMID: 36985762 PMC: 10056699. DOI: 10.3390/molecules28062790.
The Role of Adiponectin during Pregnancy and Gestational Diabetes.
Moyce Gruber B, Dolinsky V Life (Basel). 2023; 13(2).
PMID: 36836658 PMC: 9958871. DOI: 10.3390/life13020301.
Role of Adiponectin in Cardiovascular Diseases Related to Glucose and Lipid Metabolism Disorders.
Han W, Yang S, Xiao H, Wang M, Ye J, Cao L Int J Mol Sci. 2022; 23(24).
PMID: 36555264 PMC: 9779180. DOI: 10.3390/ijms232415627.
Zhao Y Front Endocrinol (Lausanne). 2022; 13:956277.
PMID: 36246919 PMC: 9554507. DOI: 10.3389/fendo.2022.956277.